` TGTX (TG Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

TGTX
vs
S&P 500

Over the past 12 months, TGTX has significantly outperformed S&P 500, delivering a return of 105% compared to the S&P 500's 9% growth.

Stocks Performance
TGTX vs S&P 500

Loading
TGTX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
TGTX vs S&P 500

Loading
TGTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
TGTX vs S&P 500

Loading
TGTX
S&P 500
Add Stock

Competitors Performance
TG Therapeutics Inc vs Peers

S&P 500
TGTX
ABBV
AMGN
GILD
VRTX
Add Stock

TG Therapeutics Inc
Glance View

Market Cap
5.6B USD
Industry
Biotechnology

TG Therapeutics Inc. stands at the intersection of innovation and ambition in the biopharmaceutical industry, with its eyes set firmly on revolutionizing the treatment of B-cell diseases. Founded by Michael S. Weiss, a proven leader in the biopharma sector, this company has carved a niche by focusing on the development and commercialization of novel therapies for cancer and autoimmune diseases. Central to its strategy is harnessing the science behind B-cells, which play a crucial role in the immune system and are often implicated in malignancies such as lymphoma and leukemia. TG Therapeutics builds its business model around creating value through its clinical development pipeline, championed by therapies like ublituximab and umbralisib. These treatments, which target different pathways within B-cells, illustrate the company’s commitment to advancing precision medicine. Revenue generation for TG Therapeutics hinges on successfully bringing its innovative therapies to market. The company follows a path similar to many in the biotech sphere: investing significantly in research and development to shepherd promising drug candidates through clinical trials. Once a therapy gains regulatory approval, TG Therapeutics moves into the commercialization phase, seeking to monetize its investments through sales. The company's ability to navigate regulatory pathways, establish strategic partnerships, and optimize its commercial efforts is crucial to converting its scientific prowess into financial returns. As a public company, it also utilizes equity financing to fund its expansive R&D endeavors, ensuring that it remains at the forefront of tackling some of the most challenging and prevalent diseases today.

TGTX Intrinsic Value
35.147 USD
Overvaluation 3%
Intrinsic Value
Price
Back to Top